Cargando…
Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276553/ https://www.ncbi.nlm.nih.gov/pubmed/34271164 http://dx.doi.org/10.1016/j.pupt.2021.102055 |
| _version_ | 1783721925228363776 |
|---|---|
| author | Ji, Hong-Long Wagener, Brant M. Ness, Timothy J. Zhao, Runzhen |
| author_facet | Ji, Hong-Long Wagener, Brant M. Ness, Timothy J. Zhao, Runzhen |
| author_sort | Ji, Hong-Long |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8276553 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82765532021-07-14 Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians Ji, Hong-Long Wagener, Brant M. Ness, Timothy J. Zhao, Runzhen Pulm Pharmacol Ther Article Elsevier Ltd. 2021-10 2021-07-13 /pmc/articles/PMC8276553/ /pubmed/34271164 http://dx.doi.org/10.1016/j.pupt.2021.102055 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Ji, Hong-Long Wagener, Brant M. Ness, Timothy J. Zhao, Runzhen Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians |
| title | Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians |
| title_full | Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians |
| title_fullStr | Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians |
| title_full_unstemmed | Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians |
| title_short | Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians |
| title_sort | fibrinolytic or anti-plasmin (nafamostat) therapy for covid-19: a timing challenge for clinicians |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276553/ https://www.ncbi.nlm.nih.gov/pubmed/34271164 http://dx.doi.org/10.1016/j.pupt.2021.102055 |
| work_keys_str_mv | AT jihonglong fibrinolyticorantiplasminnafamostattherapyforcovid19atimingchallengeforclinicians AT wagenerbrantm fibrinolyticorantiplasminnafamostattherapyforcovid19atimingchallengeforclinicians AT nesstimothyj fibrinolyticorantiplasminnafamostattherapyforcovid19atimingchallengeforclinicians AT zhaorunzhen fibrinolyticorantiplasminnafamostattherapyforcovid19atimingchallengeforclinicians |